Back to Journals » Clinical and Experimental Gastroenterology » Volume 13

Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy

Authors Dahmus J, Rosario M, Clarke K

Received 9 June 2020

Accepted for publication 8 September 2020

Published 15 September 2020 Volume 2020:13 Pages 339—350


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Wing-Kin Syn

Video abstract of "Risk of lymphoma associated with anti-TNF therapy in IBD" [ID 237646].

Views: 50

Jessica Dahmus, Michelle Rosario, Kofi Clarke

Gastroenterology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA

Correspondence: Kofi Clarke Tel +1 717-531-8741
Fax +1 717-531-6770

Abstract: Anti-tumor necrosis factor alpha (ATA) therapy plays a significant role in the treatment of moderate to severe inflammatory bowel disease (IBD). There are concerns regarding risks associated with their use, including malignancy and, specifically, lymphoma. Many previous studies have sought to determine whether there is a true link between ATA therapy in IBD and development of lymphoma. However they have been hindered by short follow-up times, few cases, and confounding factors such as previous thiopurine exposure. This review seeks to update the literature by evaluating more recent studies assessing the link between ATA monotherapy and lymphoma development. It also summarizes findings of those studies and provides additional clinical guidance pertaining to this class of biologic therapy.

Keywords: malignancy, cancer, biologics, ulcerative colitis, Crohn’s disease, hepatosplenic T-cell lymphoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]